Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson

www.jnj.com

Latest From Johnson & Johnson

Where Is J&J Investing For The Future? Cell Therapy, Gene Therapy And RNA

Janssen global head of R&D Mathai Mammen said the three areas are therapeutic modalities J&J is prioritizing for future drug development, both internally and through partnering.

Gene Therapy ImmunoOncology

What Late-Breakers To Look Out For At ASCO 2019

Delegates at this year’s ASCO meeting in Chicago will hear late-breaking clinical data for a number of studies from AstraZeneca, Novartis, Pfizer, Astellas, Merck & Co and Seattle Genetics which are set to shake up their respective markets. There will also be more clarity on where Lilly’s Lartruvo went so wrong.

ASCO Clinical Trials

J&J Plans 10 Potential Blockbuster Filings By 2023

The company outlined pharma growth drivers, including 14 currently marketed medicines that will achieve $1bn or more in sales by 2020 and 10 new filings through 2023.

Launches Business Strategies

IPA's Jain On The Journey So Far And Fires To Douse

Sudarshan Jain, the new secretary general of the Indian Pharmaceutical Alliance and ex-Abbott managing director, wears many hats, including that of a senior advisor with a private equity advisory firm. He recounts having “survived in different cultures” in his career and outlines the priorities in his new role, amid continuing questions around generic quality.

India Commercial
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register